ARTICLE
21 April 2015

CMDh Places New Restriction On Hydroxyzine-Containing Medicines

JD
Jones Day

Contributor

Jones Day is a global law firm with more than 2,500 lawyers across five continents. The Firm is distinguished by a singular tradition of client service; the mutual commitment to, and the seamless collaboration of, a true partnership; formidable legal talent across multiple disciplines and jurisdictions; and shared professional values that focus on client needs.
These measures, which encompass restrictions in use and dose, will be directly implemented by the Member States where the medicines are authorized, according to an agreed timetable.
United States Food, Drugs, Healthcare, Life Sciences

The CMDh (Coordination Group for Mutual Recognition and Decentralised Procedures—Human) has approved new measures on the use of hydroxyzine in patients at high risk of heart rhythm problems. These measures, which encompass restrictions in use and dose, will be directly implemented by the Member States where the medicines are authorized, according to an agreed timetable.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More